AI Across the Clinical Development Lifecycle
A review of the tools and services in use and in development, from protocol design to real-world evidence, with the evidence, the regulation and the open questions. Around 160 providers across twelve lifecycle stages, every claim graded, and a decision checklist for sponsors and CROs. Free to read; no email wall.
AI has moved to the operating core of clinical development. The evidence has not kept up with the claims.
The major eClinical platforms, the large CROs and most of the large Indian IT-services firms now sell AI-labelled capability across the trial lifecycle, and regulators in the United States, the European Union and India have published the frameworks by which that capability will be judged. This review maps what is actually available, what is still in development, and what the evidence says about each.
Three things stand out from the roughly 450 sources compiled for the paper. First, the maturity of AI varies sharply by lifecycle stage: patient-to-trial matching, medical coding, safety-case intake and imaging reads have peer-reviewed or regulator-recognised evidence behind them; protocol authoring, statistical programming and clinical-study-report generation have promising pilots but thin independent validation. Second, the regulatory position has clarified quickly: the FDA’s January 2025 draft guidance supplies a seven-step credibility framework, the EMA’s reflection paper and the joint EMA–FDA principles of January 2026 set expectations for the full product lifecycle, and ICH E6(R3) now requires validated, governed data systems whatever technology underlies them. Third, the gap between vendor claims and measured outcomes is wide.
Buy where the evidence is, pilot where it is not, and treat validation, data governance and skills as the cost of entry rather than an afterthought.The practical conclusion, Section 1
The paper is organised as a lifecycle map: twelve stages from protocol design to real-world evidence, each showing the tools in commercial use and those still emerging, with the platforms and governance instruments that cut across all of them. Sections 16 to 20 cover regulation, geographies, the market and the provider landscape; Sections 21 to 23 draw conclusions, map the white space and offer a checklist. Appendix A is a filterable catalogue of every provider reviewed.
Twelve stages, each with the tools in use and the tools emerging.
Vendors describe their products in their own vocabulary, which makes like-for-like comparison difficult. The paper organises the market by what a trial team actually does. The examples below are a sample; the interactive map and the catalogue list all of them, with status and evidence grade.
Six patterns across ~160 providers
Maturity follows measurability
The tools with regulator qualification or peer-reviewed evidence solve narrow problems with an expert reference standard. Tools that generate open-ended artefacts lack that anchor and are judged on vendor time-savings claims.
Vendor metrics are not outcomes
“80% faster review” describes the speed of a task, not the effect on database lock, enrolment or approval. Keep task efficiency, process efficiency, study outcomes and regulatory and patient outcomes apart; evidence at one level does not carry to the next.
Human oversight is the regulatory default, in proportion to risk
The FDA, EMA, CIOMS XIV and the draft Annex 22 all converge: the nature and extent of oversight must match intended use, consequence of error and demonstrated reliability. The 2026 agent announcements describe accept-or-reject workflows with audit logs.
Structured data is where reliability comes from
Repeatable, validated automation benefits from standardised inputs: ICH M11, USDM, CDISC and Dataset-JSON matter as much to dependable adoption as any model release.
The failure modes are documented and specific
Fabricated references, silent code errors, prompt sensitivity, model drift, automation bias and weaker performance in under-represented subgroups: all arguments for independent QC that the vendor does not supply.
Scale changes which benefit matters
The documented throughput wins are at very large volumes. Smaller sponsors realise value from avoided rework, caught errors and milestones met; their business case rests on quality and inspection readiness.
Where AI has not yet reached, and where efficiency remains
Mapping the providers against the twelve stages shows where the money has gone: study build, query generation, patient matching, case intake, imaging reads and report drafting. It also shows, by omission, where it has not. Twelve gaps, offered as hypotheses for market validation, each a place where a sponsor or CRO can still take cost out.
- The amendment cascade: tracing an amended protocol into the SAP, DMP, edit checks and eCRF
- Reconciliation, as distinct from query generation
- Medical monitoring and medical review
- Statistical design transparency for small sponsors
- The operational decision layer: RAID, status synthesis, vendor-build oversight
- Oversight of the overseers: assessing a CRO's AI under E6(R3)
- Early-phase and bioequivalence trials
- Low-volume and institutional research
- Language and locality
- Credibility assessment as a service
- Process redesign and QC sampling
- Standards readiness
Nine questions to put to the vendor, and to yourself
For a sponsor or CRO evaluating a specific AI tool or service for a specific stage, drawn from the evidence and the regulatory frameworks in the paper.
- Context of use
- Evidence
- Technique and determinism
- Validation and change control
- Human oversight
- Data governance
- Inputs and standards
- Skills and process
- Economics
A reasonable sequence for a mid-size organisation: first the structured-data foundation and SOPs for AI-assisted review; second, tools with regulator-recognised or peer-reviewed evidence in high-volume, well-bounded tasks; third, generative drafting tools with an unchanged review process; and only then agentic systems, once the validation and logging practices exist to supervise them.
The paper maps the market. Praveg can map it to you.
The review is deliberately broad. Most readers need the narrow version: which three vendors to shortlist for one stage, what evidence to demand from them, how to write the credibility-assessment plan the FDA framework expects, or which SOP, QC-sampling and role changes make AI-assisted review inspectable under ICH E6(R3).
- Stage-specific shortlist and vendor evidence review
- Credibility assessment and GAMP 5 Appendix D11 qualification plans, sized for mid-size sponsors and CROs
- Process redesign, QC sampling and SOP changes for AI-assisted review
- Standards readiness: USDM, CDISC and Dataset-JSON foundations
- Sponsor-side oversight of a CRO’s AI under E6(R3)
- Briefings for leadership teams and boards
Disclosure. Praveg advises sponsors and CROs on biometrics set-up and AI adoption and is developing offline, deterministic-first practitioner tools for data management and biostatistics. None is cited as evidence in the paper, and readers evaluating any vendor, including Praveg, should apply the checklist in Section 23.
About this white paper
What does the white paper cover?
Around 160 providers of AI tools and services across twelve clinical development stages: protocol design and simulation, feasibility and site selection, recruitment and eligibility screening, start-up and TMF, study build and data capture, data management and medical coding, monitoring and RBQM, imaging and digital endpoints, safety and pharmacovigilance, biostatistics and statistical programming, medical writing and submissions, and post-marketing and real-world evidence. It also covers the cross-cutting platforms, the regulation in the US, EU and India, the services landscape including Indian IT services, the market data, six evidence patterns, twelve white-space gaps and a decision checklist.
Is the paper free, and do I need to register?
Yes, it is free, and no. Read the interactive version online, download the PDF, or both. Praveg does not put its research behind an email wall. If you would like a tailored analysis for your organisation, use the enquiry form on this page.
How were the claims in the paper graded?
Every quantitative claim is tagged as vendor-reported, customer-reported, peer-reviewed, conference or preprint, or regulator-recognised. A product announcement is treated as evidence that a product exists, not that its claimed performance has been demonstrated. Where two sources conflict, both figures are given. Around 450 public sources were compiled and 417 are cited.
Which regulations does it cover?
ICH E6(R3) and its Annex 2, the FDA draft guidance on AI to support regulatory decision-making (January 2025) and its seven-step credibility framework, the EMA reflection paper and the joint EMA-FDA guiding principles (January 2026), the EU AI Act, GAMP 5 Second Edition Appendix D11, the FDA Computer Software Assurance guidance, the draft EU Annex 22, CIOMS Working Group XIV, India's DPDP Rules 2025 and ICMR's AI guidelines, with notes on China, Korea, the UK and the EHDS.
Who is the paper for?
Decision-makers in sponsors, CROs and clinical technology or service organisations who must choose where to invest, what to validate and what to ask vendors: heads of clinical operations, data management, biostatistics, pharmacovigilance, digital and IT, quality, and procurement.
Can Praveg produce a version specific to my organisation?
Yes. Praveg provides tailored analysis of this landscape for individual sponsors, CROs and service providers: a shortlist for a specific stage, a vendor evidence review, a credibility-assessment plan under the FDA framework, or the process and SOP changes that make AI-assisted review inspectable. Send an enquiry from this page or email info@pravegcs.com.
How should the paper be cited?
Praveg Consultancy Services LLP (2026). AI Across the Clinical Development Lifecycle: a review of tools and services in use and in development. pravegcs.com.
Read it, then let’s talk.
Thirty minutes to understand what you are evaluating and say plainly whether Praveg can help.